Zopiclon Synthon is commonly used for the short-term symptomatic management of severe, distressing insomnia in adults. Its use is generally relevant in situations where disturbed sleep leads to symptoms that interfere with daily functioning, supporting treatment for conditions characterized by periods of heightened symptoms related to sleep loss.

The agent is applied to address a cluster of symptoms including difficulty falling asleep, frequent nocturnal awakenings, and premature final awakening. It is used during phases of increased distress or discomfort, acting as a form of short-term symptomatic assistance to support temporary symptom stabilization.

By assisting with the impact of sleep disturbances, Zopiclone helps ease the impact of these symptoms on routine activities and assists with maintaining functional stability and general comfort.

Quick Fact: Relief for Fragmented Sleep
Zopiclone contributes to improved comfort during periods of heightened symptoms by assisting with nocturnal awakenings.

The eligibility for Zopiclon Synthon is strictly defined by regulatory authorities and depends on age, specific health conditions, and prior history with sedative-hypnotics. The medicine is indicated solely for the short-term symptomatic management of insomnia in adults.

Populations for Whom Use is Prohibited (Contraindicated)

Category	Contraindication	Status
Age	Children and adolescents (under 18 years)	Prohibited
Severe Conditions	Severe Hepatic Insufficiency, Severe Respiratory Failure, Severe Sleep Apnoea Syndrome, Myasthenia Gravis	Prohibited
Prior History	History of complex sleep behaviors (e.g., sleepwalking) after taking zopiclone or similar drugs	Prohibited
Allergy	Known hypersensitivity to the active ingredient or excipients	Prohibited

Conditional Eligibility and Restrictions

Use is subject to a reduced initial dose (e.g., 3.75 mg instead of 7.5 mg) in the following special populations, as mandated by regulatory documents:

• Elderly Patients
• Patients with Impaired Renal Function
• Patients with Mild to Moderate Hepatic Dysfunction
• Patients with Chronic Respiratory Insufficiency

Pregnancy and Lactation: Zopiclon Synthon is not recommended during pregnancy, and it should not be administered to breastfeeding mothers, as the substance is known to be excreted into breast milk.

Interactions with other medicines and products

Zopiclone’s interaction profile is primarily defined by additive central nervous system (CNS) depressant effects and alterations to its metabolic clearance by liver enzymes.

CNS Depressants and Alcohol

Concomitant use with alcohol is contraindicated due to a significant risk of increased adverse effects, including profound sedation, respiratory depression, coma, and death. Similar, potentially fatal, additive depressant effects occur when zopiclone is combined with opioids, leading to a strong warning that this combination should be reserved only for cases where alternatives are inadequate. Other CNS depressants, such as other sedative-hypnotics, tranquilizers, antidepressants, antipsychotics, and certain antihistamines, also carry a heightened risk of excessive sedation and complex sleep behaviors like sleep-driving.

Pharmacokinetic Interactions

Zopiclone is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver. Inhibitors of this enzyme, such as ketoconazole, erythromycin, and cimetidine, can substantially reduce zopiclone's clearance from the body, leading to increased plasma concentrations and a greater potential for enhanced sedative effects, often requiring a dose reduction. Conversely, potent CYP3A4 inducers, such as rifampicin and apalutamide, can accelerate zopiclone's metabolism, significantly decreasing its concentration and reducing its hypnotic effectiveness. Dosage adjustments may be necessary with these concurrent medications.

Zopiclon Synthon acts within the central nervous system as a positive allosteric modulator of the GABA-A receptor complex. This receptor is a ligand-gated chloride ion channel situated postsynaptically on neuronal membranes, primarily mediating the inhibitory effects of the neurotransmitter gamma-aminobutyric acid (GABA).

The molecule binds to a distinct regulatory site, often referred to as the benzodiazepine-binding site, located at the interface between the alpha and gamma subunits of the pentameric GABAA receptor. Unlike some non-benzodiazepines, Zopiclon Synthon exhibits comparable binding affinity for GABAA receptors containing alpha1, alpha2, alpha3, and alpha5 subunits.

This allosteric interaction induces a conformational change in the receptor structure, increasing the affinity of GABA for its primary binding site and augmenting the frequency of chloride channel opening. The resulting influx of negatively charged chloride ions ( Cl^-) into the neuron causes hyperpolarization of the neuronal membrane. This increase in the transmembrane potential renders the neuron less excitable, reducing its probability of firing an action potential. This widespread potentiation of GABAergic inhibitory neurotransmission leads to a generalized decrease in systemic neuronal activity and modulation of central excitability.

Zopiclon Synthon is designated exclusively for oral administration as a film-coated tablet. The administration regimen focuses on a single, nightly intake to support short-term management. The tablet must be taken immediately before retiring for the night as a single dose, and it is crucial that the user is able to commit to 7 to 8 hours of uninterrupted sleep after administration. The dose should be swallowed whole with water and must not be crushed or chewed.

---

Official Dosing and Administration Schedule

The dosing regimen is strictly defined and should not be exceeded. The maximum dose is mathbf7.5 mg for non-elderly adults, while lower starting doses are mandated for vulnerable groups. The total duration of therapy, including any gradual dose reduction (tapering off), is strictly limited.

Patient Group	Starting / Standard Dose	Maximum Duration
Non-Elderly Adults	mathbf7.5 mg	mathbf4 weeks
Older Adults	mathbf3.75 mg	mathbf4 weeks
Hepatic or Renal Impairment	mathbf3.75 mg	mathbf4 weeks

Use in patients under mathbf18 years of age is not recommended. A second dose must not be taken during the same night if the first dose is missed or ineffective. Administration with a heavy or high-fat meal should be avoided as it may delay the hypnotic effect.

Recent Clinical Evidence

Overview of Clinical Research

The initial research explored the medication's intended use for acute, non-chronic insomnia and the associated difficulty falling or staying asleep. Clinical studies began by investigating the medication's intended action on the central nervous system, particularly its interaction with GABA-A receptors.

Key Study Findings

Sleep Parameters

Randomized controlled trials (RCTs) found differences in sleep metrics between groups receiving the medication and those receiving placebo. Research suggests that for some individuals, the medication may be associated with:

• A reduced time to fall asleep (decreased sleep latency).
• An increased total sleep duration (often cited in short-term use).
• A reduction in the number of times waking up during the night.

It is important to note that the absolute average benefit in clinical trials compared to placebo has generally been reported as small, often in the range of 15-30 minutes of increased total sleep time.

Duration and Pharmacokinetics

Research on the medication's elimination half-life, which ranges from approximately 3.5 to 6.5 hours in younger adults, indicates its suitability for short-term use in managing insomnia.

• Impact in Older Adults: Studies indicate the elimination half-life is often prolonged to around 7 hours in older patients, which may increase the potential for residual daytime effects compared to younger adults.
• Long-Term Use: Due to the risk of tolerance and dependence, clinical trials and regulatory guidance emphasize that the medication is primarily studied and intended for short-term treatment (typically not exceeding 2 to 4 weeks).

Off-Label Explorations

Studies have been conducted to evaluate outcomes for specific subgroups, including participants with hepatic (liver) or renal (kidney) impairment. The findings from these subgroups provide an initial description of outcomes, often noting a prolonged elimination half-life in those with hepatic impairment.

Key Studies & References

1. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation (Comparative review of Z-drugs including zopiclone)
2. Public Assessment Report Scientific discussion Zopiclone Jubilant 7.5 mg, film-coated tablets (zopiclone) NL/H/2914 (Regulatory document detailing pharmacokinetics and established efficacy)

Common questions about Zopiclon Synthon (FAQ)

Q: Is Zopiclon Synthon the same as Ambien, or are they different?

A: Zopiclone (the active ingredient in Zopiclon Synthon) and zolpidem (commonly known as Ambien) are both classified as 'Z-drugs' used for sleep. However, regulatory documents confirm they belong to different chemical classes. Zopiclone is from the cyclopyrrolone class, while zolpidem is an imidazopyridine, meaning they are chemically distinct compounds.

Q: What is the difference between Zopiclon Synthon and zolpidem?

A: Official information indicates that while both are Z-drugs, they have slightly different properties. Zopiclone generally has a longer elimination half-life—the time it takes for the drug concentration to decrease by half—compared to immediate-release zolpidem. This difference may be a factor when considering the drug's duration of action and the potential for next-day effects.

Q: Does taking Zopiclon Synthon affect driving or operating machinery?

A: Yes, official safety information explicitly cautions against engaging in hazardous activities, such as driving or operating machinery, following administration of this medication. This risk is primarily due to potential effects like drowsiness and dizziness, and it is heightened if the dose is higher than recommended or if alcohol is consumed. Official documentation notes the importance of being able to commit to 7 to 8 hours of uninterrupted sleep after taking the medication.

Q: What happens if a dose of Zopiclon Synthon is forgotten or missed?

A: Regulatory patient information states that if a dose is missed by bedtime, the dose should be skipped unless the user can still be assured of 7 to 8 hours of uninterrupted sleep after taking it. It is explicitly noted that a second dose must not be taken during the same night to compensate for the missed dose.

Q: Does Zopiclon Synthon interact with common pain relievers like ibuprofen?

A: Regulatory warnings primarily focus on interactions with CNS depressants like opioids, as well as drugs that affect liver enzymes (CYP3A4 inhibitors/inducers). Standard non-opioid pain relievers like ibuprofen are generally not listed in official documents as causing a major pharmacokinetic interaction with zopiclone. Health regulators note the importance of communicating all medications and supplements being taken to a healthcare professional.

Q: What is the 'half-life' of Zopiclon Synthon?

A: The elimination half-life of zopiclone, according to official product characteristics, is approximately 3.5 to 6.5 hours in younger adults. This time indicates how quickly the drug is cleared from the body. In older adults or those with impaired liver function, the half-life can be prolonged, which may increase the risk of residual daytime effects.

Q: Can Zopiclon Synthon cause any strange dreams or nightmares?

A: Yes, official regulatory documents list nightmares as an uncommon side effect. Other psychiatric effects, such as hallucinations or abnormal dreams, have also been reported, usually in rare instances.

Q: What is the recommended storage temperature for Zopiclon Synthon tablets?

A: Official storage instructions state that the tablets must be stored at or below 25 C (or at standard room temperature). They must also be kept in the original container, protected from light and moisture, and stored securely out of the sight and reach of children.

Q: How does Zopiclon Synthon affect the different stages of sleep?

A: Studies and official information indicate that zopiclone alters the sleep profile. It works by reducing the time it takes to fall asleep and decreasing the shallowest sleep stage (Stage I). It tends to increase the duration of Stage II sleep and generally preserves or prolongs the deeper slow-wave stages of sleep and REM sleep.

Q: What are the rare but serious side effects to look out for with Zopiclon Synthon?

A: Serious, though rare, side effects noted in official warnings include severe Hypersensitivity Reactions (like angioedema or anaphylaxis). The most widely warned-about serious risk is Complex Sleep Behaviors—doing things like driving or preparing food while not fully awake and having no memory of the event.

Q: What happens when you stop taking Zopiclon Synthon after using it for a while?

A: Official safety constraints warn of a risk of Withdrawal Symptoms (such as rebound insomnia, anxiety, and mood changes) when discontinuing the medication. Regulatory guidance highlights the importance of gradual dose reduction (tapering off) rather than abrupt cessation to help minimize these risks.

Q: Is it safe to take Zopiclon Synthon with anti-depressant medications?

A: Antidepressants are categorized as CNS depressants in the official interaction profile. Combining them with zopiclone may result in an enhanced central depressive effect, leading to symptoms like excessive sedation. Official warnings note that the decision to combine these two types of medications requires professional medical guidance.

Q: What should be done if an overdose of Zopiclon Synthon is suspected?

A: Regulatory documents on overdose state that symptoms can include severe drowsiness, confusion, loss of muscle tone, and possibly coma. If an overdose is suspected, immediate emergency medical attention should be sought. Management focuses on general symptomatic and supportive measures.

Q: Are there any major food or supplement interactions with Zopiclon Synthon?

A: Official administration instructions advise that the medication should not be taken with a heavy or high-fat meal, as this may delay the onset of the hypnotic effect. Additionally, certain supplements that affect the CYP3A4 liver enzyme may potentially change the blood concentration of the drug, according to regulatory pharmacokinetic data.

Q: Is Zopiclon Synthon prescribed for anxiety as well as sleep?

A: No. According to the official therapeutic indications, Zopiclon Synthon is indicated solely for the short-term symptomatic management of insomnia in adults when the disorder is debilitating or causing severe distress. It is not indicated for the treatment of anxiety.

Q: Are there generic versions of Zopiclon Synthon available?

A: The active ingredient, zopiclone, is widely available as a generic product, in addition to being marketed under various brand names. These different formulations are listed in the drug registers of major regulatory authorities.

Q: Can Zopiclon Synthon cause memory problems or 'blackouts'?

A: Yes, regulatory safety information includes amnesia (memory loss) as a documented side effect. This refers to anterograde amnesia, which is the inability to recall events that occurred after the tablet was taken, often linked to the occurrence of complex sleep behaviors.

Q: Does Zopiclon Synthon make a person feel 'high' or euphoric?

A: Official warnings note that combining zopiclone with opioid medications can lead to an enhancement of euphoria, which can increase the risk of dependence. Euphoria is not listed as a common or expected side effect when the medication is taken alone as prescribed.

Q: Is it true that Zopiclon Synthon can cause sleepwalking or other unusual behaviors?

A: Yes, official warnings highlight the risk of Complex Sleep Behaviors (CSBs). These behaviors can include sleepwalking, sleep-driving, making phone calls, or preparing and eating food while not fully awake, with the patient having no memory of the event. Official documentation states that the medication should be discontinued if a Complex Sleep Behavior occurs.

Q: Why is Zopiclon Synthon a controlled substance in some places?

A: Zopiclone is scheduled as a controlled substance in certain countries and regions due to the risk factors documented in official information. These risks include the potential for drug abuse, the development of physical and psychic dependence, and the possibility of misuse.

Q: Is it safe for a breastfeeding mother to use Zopiclon Synthon?

A: No. Official safety information for Zopiclon Synthon states that the medication is not recommended for use in breastfeeding mothers. This constraint is due to evidence that the active substance is known to be excreted into breast milk.

Storage and Disposal of Zopiclone Synthon: Official Requirements

Zopiclone tablets must be stored securely to maintain product stability and ensure safety.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at or below 25 C, or at room temperature (15 C to 30 C).
Protection	Protect from light and store in a dry place.
Packaging	Store in the original container and keep tightly closed. Do not use beyond the labeled expiry date.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Zopiclone Synthon must be disposed of according to local requirements. The medicine should generally not be disposed of via wastewater or household waste unless specifically advised by local authorities. Disposal is typically managed through local drug take-back programs.